We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma.
- Authors
Ho, J.; Yang, L.; Banihashemi, B.; Martin, L.; Halpenny, M.; Atkins, H.; Sabloff, M.; McDiarmid, S. A.; Huebsch, L. B.; Bence-Bruckler, I.; Giulivi, A.; Allan, D. S.
- Abstract
Relapsed disease remains a major obstacle following autologous haematopoietic SCT (HSCT) for non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Studies regarding the importance of detectable tumour cells in PBSC collections have been inconclusive. Patients undergoing autologous HSCT for NHL and MM between 2001 and 2006 were enrolled (n=158). PBSC grafts were assessed for clonal IgH CDR3 gene rearrangements using qualitative semi-nested PCR. In comparison to patients with PCR-positive PBSC grafts, patients negative for detectable disease had no improvement in overall survival (OS) or PFS for MM (P=0.91 and 0.91) or NHL (P=0.82 and 0.85). Further, no significant difference in OS was observed between patients with PCR-positive compared with PCR-negative PBSC grafts with aggressive NHL histology (P=0.74) or indolent disease (P=0.29). Patients with contaminating tumour cells in autologous PBSCs do not have worsened OS or PFS in MM or NHL. Tumour cells detected by sensitive molecular methods in PBSC collections may be distinct from cells contaminating marrow and appear to have limited utility in identifying patients with MM and B-cell NHL who would benefit from purging strategies.Bone Marrow Transplantation (2009) 43, 223–228; doi:10.1038/bmt.2008.318; published online 29 September 2008
- Subjects
AUTOGRAFTS; DISEASE relapse prevention; LYMPHOMAS; BONE marrow purging; MULTIPLE myeloma; PATIENTS
- Publication
Bone Marrow Transplantation, 2009, Vol 43, Issue 3, p223
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/bmt.2008.318